Pharmacy and Wellness Review
Volume 4

Issue 1

Article 5

January 2013

Truvada® Recommended by FDA Committee for Pre-exposure
Prophylaxis in High-Risk HIV-Negative Individuals
Justin Steele
Ohio Northern University

Emily Blum
Ohio Northern University

Alison Steinbrunner
Ohio Northern University

Lara Long
Ohio Northern University

Andrew M. Roecker
Ohio Northern University, a-roecker@onu.edu

Follow this and additional works at: https://digitalcommons.onu.edu/paw_review
Part of the Infectious Disease Commons, Medical Pharmacology Commons, and the Pharmaceutics
and Drug Design Commons
This Article is brought to you for free and open access by
the ONU Journals and Publications at
DigitalCommons@ONU. It has been accepted for
inclusion in Pharmacy and Wellness Review by an
authorized editor of DigitalCommons@ONU. For more
information, please contact digitalcommons@onu.edu.

Infectious Disease

Truvada® Recommended by FDA Committee for
Pre-exposure Prophylaxis in High-Risk HIV-Negative Individuals
Justin Steele, fifth-year pharmacy student from Canton, Ohio; Emily Blum, fourth-year pharmacy student from Buffalo, N.Y.;
Alison Steinbrunner, fourth-year pharmacy student from New Carlisle, Ohio; Lara Long, fifth-year pharmacy student from
Terre Haute, Ind.; Andrew M. Roecker, PharmD '00, BCPS, professor of pharmacy practice, chair of the department
of pharmacy practice
Abstract
Once-daily combination tenofofovir disoproxil fumarate
(TDF) and emtricitabine (FTC) has received Food and Drug
Administration (FDA) approval for use in pre-exposure prophylaxis (PrEP) against Human Immunodeficiency Virus
(HIV) infection in high-risk individuals. In clinical trials, FTC/
TDF has been shown to reduce the risk of HIV acquisition by
62 percent in sexually active heterosexual men and women.
Similarly, use of FTC/TDF demonstrated a 44 percent reduction in HIV infection within the men who have sex with men
population.7 When used compliantly and in conjunction with
safe sex practices, it appears that FTC/TDF can play an
important role in reducing the impact and incidence of HIV
·infection.
Introduction
On July 16, 2012, the United States Food and Drug Administration approved Truvada®, a combination of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC), as the first
drug indicated for pre-exposure prophylaxis (PrEP) against
Human Immunodeficiency Virus (HIV) infection in high-risk
adults.1 Although neither drug component is new, once-daily
combination FTC 200 mg/TDF 300 mg has been shown to
decrease the chance of HIV infection by approximately 62
percent.2 When taken as directed and used as part of a comprehensive set of safe-sex practices, FTC/TDF appears to
demonstrate significant potential in reducing the incidence
of HIV transmission both within the United States and worldwide.
Typical HIV patients present with varying symptoms depending on the stage of infection. In the first few weeks, an
HIV infected individual may appear asymptomatic, or experience flu-like symptoms including fever, headache, rash or
sore throat As the infection progresses, plasma CD4+ counts
decrease, resulting in a loss of immune function, increasing
vulnerability to opportunistic infections, and ultimately leading to acquired immunodeficiency syndrome (AIDS).3 FTC/
TDF acts as a combination reverse transcriptase inhibitor
(NRTI). Both FTC and TDF are pro-drugs that are converted
to active nucleoside/nucleotide analogs in the body, which
then compete for incorporation into HIV DNA. Incorporation
of the active drug causes termination of HIV DNA chain
growth and inhibits activity of viral reverse transcriptase,
which prevents disease development by blocking both viral
genome incorporation into host cell DNA and viral replication.4
Those at the highest risk for HIV infection include men who
have sex with men, African-Americans, and young individuJanuary 2013 Volume 4, Issue 1

als aged 13 to 29 years. Since there is currently no cure for
HIV, the associated health complications may be avoided by
preventing infection with the virus. FTC/TDF may prove to
be an effective tool in reducing HIV transmission within high
risk populations by preventing infection before exposure to
the virus even occurs. Additionally, sexual partners of HIV
infected individuals may also benefit from PrEP with FTC/
TDF. It is therefore worthwhile for the modern-day pharmacist to have a strong background on HIV treatment and prevention methods, as well as become educated on the side
effects and counseling points associated with FTC/TDF.s
Efficacy in Research
Several trials have been published in the New England Journal of Medicine evaluating the efficacy of PrEP with FTC/
TDF. These studies showed promising results in several
populations, including single heterosexual men and women,
heterosexual couples and men who have sex with men.
Within these populations, FTC/TDF use provided a significant reduction in the incidence of HIV as compared to placebo.2,6.7
The Partners PrEP study, a randomized, double-blind, placebo-controlled trial performed by Baeten et al., evaluated
the protective effects of once daily FTC/TDF in heterosexual,
HIV-1-serodiscordant couples (one partner was infected with
HIV-1 while the other was not). To be included in the study
population, heterosexual couples were required to be HIVserodiscordant, free of hepatitis B virus, not pregnant or
breast-feeding, and had not received any previous antiretroviral medications. After enrollment, the HIV-seronegative
participants of 4,747 couples were randomly assigned to receive 300 mg TDF daily, FTC/TDF (300 mg/200 mg) daily, or
placebo for a period up to 36 months. At the conclusion of
the trial, researchers found a 75 percent reduction in HIV
acquisition due to FTC/TDF as compared to placebo
(p<0.001). Furthermore, there was no significant difference
between the TDF monotherapy and FTC/TDF combination
therapy groups (p=0.23).6
The TDF2 study, a randomized trial by Thigpen et al., examined the effects of daily FTC/TDF versus placebo in sexually
active men and women from Botswana. To be eligible for
inclusion, participants were required to be between 18 and
39 years of age, HIV seronegative, free of chronic illnesses
and hepatitis B virus and not pregnant or breast-feeding.
After enrollment, a total of 1,219 study participants were
randomized and followed for 1,563 person-years (median,
1.1 years; maximum, 3.7 years) with monthly HIV testing.
Upon conclusion, the intent-to-treat analysis of FTC/TDF
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provided a 62.2 percent reduction in HIV infection as compared to placebo (p=0.03). In the as-treated analysis, data
was limited to participants who became infected within 30
days of their last self-reported dose of medication, yielding a
total of four infections within the FTC/TDF group and a protective efficacy of 77.9 percent (p=0.01). However, within the
treatment group, mean plasma drug levels were significantly
lower in participants that became infected as compared to
plasma levels of participants that did not become infected
(0.3 ng/mL versus 30.6 ng/mL for TDF, p=0.007; and 0.5 ng/
mL vs 103.3 ng/mL for FTC, p=0.009). Therefore, these
results show that while FTC/TDF can provide a significant
reduction in the risk of HIV infection, its efficacy in PrEP is
largely dependent on adherence to the medication regimen.2
FTC/TDF has also shown desirable efficacy of HIV prophylaxis in the men who have sex with men population. In the
iPrEx study, a randomized, placebo-controlled trial by Grant
et al., 2,499 HIV-negative men or transgender women who
have sex with men were randomly assigned to receive once
daily FTC/TDF or placebo.7 Participants were then tested for
HIV infection monthly and were followed for 3,324 personyears (median, 1.2 years; maximum, 2.8 years). During the
follow-up period, a total of 100 participants became infected;
36 in the FTC/TDF group and 64 in the placebo group, resulting in a 44 percent reduction in HIV infection (p=0.005).7
Furthermore, within the treatment group, plasma levels of
FTC/TDF were detected in 9 percent of infected subjects,
whereas detectable levels were discovered in 51 percent of
non-infected subjects. Similar to other studies, these results
further demonstrate the importance of adherence, as there is
a strong relationship between detectable plasma levels of
FTC/TDF and its prophylactic effect. 2.1
The Partners PrEP, TDF2, and iPrEx studies all shared a common limitation in that each study included participants with
an acute HIV infection that was missed during the enrollment
process.2.6, 7 The Partners PrEP enrolled 14 participants with
current HIV infection of which eight received either TDF or
FTC/TDF.6 TDF2 study enrolled a total of three infected participants of which two were entered into the treatment
group.2 In the iPrEX study, 10 participants were found to
have plasma HIV RNA after enrollment of which five had
symptoms of acute viral syndrome at enrollment.7 A major
concern with initiating FTC/TDF therapy in an HIV positive
patient is the risk of retroviral resistance. In the TDF2 study,
one enrolled HIV-infected participant receiving FTC/TDF,
developed reverse transcriptase resistance mutations at high
levels of approximately 100 percent, thereby limiting use of
reverse transcriptase medications as an HIV treatment therapy.2 Of the participants enrolled with HIV infection in the
Partners PrEP study, two developed resistance.6 To avoid the
issue of resistance, acute HIV infections can be screened for,
not only overt symptoms but also testing for HIV antibodies
if no symptoms are present, and additional testing for HIV
RNA if possible when HIV antibodies results are negative. 1
It is important to recognize that each of the three clinical trials performed included a comprehensive package of HIV prevention services in addition to the FTC/TDF therapy. These
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services included risk reduction (RR) counseling, screening
and treatment of sexually transmitted infections (ST!s) and
free condoms.2.6,7 Participants in the Partners PrEP study
also received condom counseling and referral for male circumcision.6 The TDF2 study performed individualized counseling on RR during quarterly visits and at any other visits
upon request. 2 When using FTC/TDF as PrEP HIV, prevention
services are an integral part of the therapy and must be included in order to best prevent HIV infections.

Special Considerations
FTC/TDF is a renally cleared drug, and precautions must be
taken with patients who are using FTC/TDF for PrEP and
have impaired renal function. If the patient's renal function is
<60 mL/min, FTC/TDF use is not recommended.a The patient's creatinine clearance (CrCl) should be measured every
three months initially, then every six months.9
Based on a lack of clinical studies, FTC/TDF is not recommended for pregnant or lactating women. In the TDF2 study,
women could not continue with the study if they had a positive pregnancy test; however, of the 107 pregnancies, neither
the rate of pregnancy nor the rate of fetal loss differed between the study groups (p=0.58, and p=l.00, respectively).2
The Partners PrEP trial also excluded women who became
pregnant but were allowed to return after the pregnancy.s
Both FTC and TDF are currently used to prevent perinatal
transmission from HIV-infected women to their newborns.
Currently, there is no evidence of adverse effects on fetuses
exposed to FTC and TDF; however, the data is not complete
because the combination of FTC/TDF has not been clinically
tested yet due to pregnant women being removed from clinical studies, so health care providers should use their best
clinical judgment. Pregnancy tests should be done routinely
every two to three months in women taking FTC/TDF for
PrEP.9
Bone mineral density loss is another side effect that must be
taken into consideration. Currently, long-term studies have
not been performed to determine the exact effects of FTC/
TDF when used as PrEP on bone mineral density. The TDF2
study did look at bone mineral density in a subset of the participants. The results showed a decline in bone mineral density in the forearm, hip, and lumbar spine in participants who
received FTC/TDF versus placebo (p=0.004 at the forearm,
p<0.001 at hip and lumbar spine).2 These results do not
show long-term effects of FTC/TDF on bone mineral density,
and more studies need to be done to determine these longterm effects. Therefore, patients taking FTC/TDF should receive regular bone mineral density tests.

Pharmacist Information
Use of FTC/TDF as PrEP is aimed at high risk individuals including those with HIV-positive partners or those who engage in sexual activity within a high prevalence area and
have one or more of the following characteristics: inconsistent or no condom use, diagnosis of ST!, exchange of sex
commodities, use of illicit drugs or alcohol dependence,
incarceration or partner of unknown HIV status and any of
the above risks.a FTC/TDF should not be used as PrEP for
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HIV if the patient is already HIV-positive or if HIV status is
unknown.8 An HIV test must be performed before taking
FTC/TDF for PrEP as well as every three months during therapy to avoid the possibility of drug resistance.8 At each three
month visit, clinicians should test patients for hepatitis B
infection and STis. No more than 90 pills should be dispensed at a time to ensure FTC/TDF PrEP is not being taken
concurrently with an undiagnosed HIV infection. 9

have an important role in patient education of proper use of
FTC/TDF. In this way, pharmacists can maximize the protective effects of FTC/TDF, thereby reducing the transmission of
HIV and overall impact of the disease.
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Project RESPECT, a multicenter randomized controlled trial,
looked into three different RR counseling styles in order to
determine the most efficacious approach.10 Participants received either enhanced counseling (four session interviews
of 200 minutes total), brief counseling (two sessions of 40
minutes total), or didactic messages (two sessions without
engagement of ten minutes total). Development of ST!s was
lower in the enhanced counseling as well as brief counseling
arm (11.S percent and 12 percent) compared to the didactic
messages arm (relative risk 14.6 percent, 0.81; 95 percent
confidence interval, 0.67-0.98).10 These results are clinically
significant in that even spending as few as two 20-minute
sessions with a patient, engaging him or her through a more
conversational way of counseling can improve healthy RR
habits. Based on these results, pharmacists should make an
effort to create a dialogue between their patients, particularly those at risk, about the importance of condom use as
well as avoiding risky behaviors such as multiple partners,
using injectable drugs and engaging in anal intercourse.
Conclusion
There is currently no cure for HIV, therefore, all forms of prevention, including FTC/TDF should be implemented to avoid
later health ramifications. Currently, trials have been conducted in three populations of high-risk individuals including
men who have sex with men, heterosexual individuals and
heterosexual couples with one seropositive partner, showing
a significant protective effect of FTC/TDF against transmission of HIV. However, the benefit is only seen in combination
with safe sex practices and strict compliance. Pharmacists
January 2013 Volume 4, Issue 1
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